Executive Brief — Portfolio Infrastructure Maturity

Your portfolio is scaling. Your infrastructure isn't keeping up.

Today's top 20 pharma companies operate 20–30+ simultaneous programs. Merck has 30+ in Phase 3 alone. Pfizer is planning ~20 pivotal starts in 2026. AstraZeneca targets 20 new medicines by 2030. CDOs and CIOs own the gap between portfolio ambition and the data infrastructure required to support it. The hidden cost is the non-compounding work of manually connecting instruments, systems, and sites for every program.

Get the Executive Brief Explore the Architecture

Portfolio Scale — The Numbers

30+

Merck Phase 3 Programs (Merck Pipeline Review, 2025)

~20

Pfizer Pivotal Starts, 2026 (JPM Healthcare Conference, Jan 2026)

AstraZeneca New Medicines by 2030 (AstraZeneca FY2024 Results)

$236B

Patent Expirations, 2025–2030 (Evaluate Pharma, 2024)

77%

Expect AI Adoption Within 2 Years — Lack Infrastructure (Pistoia Alliance, 2024)

63%

Rank AI as Top Investment — Lack the Data Foundation (Pistoia Alliance, 2025)

Trusted by 6 of the 10 largest pharmaceutical companies in the world

And leading biotechs and agrochemical companies

6 of 10

Top-10 Pharma Companies

150+

Vendors

400+

Instrument Models

100+

Analytical Techniques

The Portfolio Problem

Every New Program Multiplies Infrastructure Demands Linearly

4× Data Complexity — Each new program adds instruments, formats, LIMS integrations, and validation requirements that do not compound from previous work

5–10% Flat Headcount — IT and lab informatics teams grow at 5–10% annually while program counts grow 30–50%

Siloed Systems — ELN, LIMS, CDS, and instrument data systems operate independently, requiring manual bridges for every cross-system query

0% Compounding — Project-based integration work is discarded after each engagement. Nothing carries forward to the next program

What You Get

Three Deliverables, Custom to Your Organization

Infrastructure Maturity Assessment

Your organization scored across the principles: Integration, Context, Intelligence, and AI-Enabled Decisions. See where you stand today and where the investment compounds.

Portfolio Scaling Roadmap

A phased plan from current state to portfolio-scale infrastructure. Each phase shows expected compounding returns on integration investment, headcount efficiency, and data reuse.

Reference Architecture

Technical architecture showing how the ICAD model maps to your current systems — LIMS (Laboratory Information Management System), ELN (Electronic Lab Notebook), CDS (Chromatography Data System), and cloud data lake.

“There has been a process of democratization of data. It is really easy, possible to access and to find information. And that’s a huge benefit.”

Ralph Haefeli, Global Head Technical Research and Development IT, Novartis

What the Brief Covers

Custom Analysis for Your Portfolio Infrastructure

ICAD maturity scoring Where your organization stands on Integration, Context, Intelligence, and AI readiness
Headcount efficiency modeling How infrastructure investment translates to throughput without proportional team growth
Data reuse analysis Which integration and contextualization investments compound across your portfolio
Regulatory readiness assessment 21 CFR Part 11, EU GMP Annex 11, and FAIR data readiness mapped to your current stack
Reference architecture From engagements with pharma organizations at similar portfolio scale

Get the Portfolio Infrastructure Executive Brief

Custom analysis for your organization. We assess your infrastructure maturity across the four principles, model your headcount efficiency gains, and deliver a reference architecture mapped to your current systems.